OncoMatch/Clinical Trials/NCT05769010

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases

Is NCT05769010 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SHR-A1811 and Pyrotinib for metastatic breast cancer.

Phase 2RecruitingHenan Cancer HospitalNCT05769010Data as of May 2026

Treatment: SHR-A1811 · Pyrotinib · Bevacizumab — This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: HER2 (ERBB2) overexpression (HER2-positive)

HER2-positive

Required: HER2 (ERBB2) low expression (HER2-low)

HER2-low

Disease stage

Metastatic disease required

Prior therapy

Cannot have received: antibody-drug conjugate (trastuzumab deruxtecan, DS-8201a)

Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor

Lab requirements

Blood counts

adequate function of major organs

Kidney function

adequate function of major organs

Liver function

adequate function of major organs

Adequate function of major organs

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify